• Explore /
  • Poster
  • / Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.

Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.

Abstract Poster

Authors

null

Munaf Alkadimi

University of Texas Health science center at San Antonio, San Anonio, TX

Munaf Alkadimi , Amanda Moore , Christopher R Frei , Kelly R Reveles , Lance Brannman , Ion Cotarla , Andrew Frankart , Tiernan Mulrooney , Paromita Datta , Jennifer Whitehead , Kathleen Franklin , Renee Reichelderfer , Madison H. Williams , Ryan A. Williams , Sarah Allison Smith , Xavier Jones , Zohra Nooruddin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8554)

DOI

10.1200/JCO.2022.40.16_suppl.8554

Abstract #

8554

Poster Bd #

181

Abstract Disclosures

Similar Posters

First Author: John M. Varlotto

First Author: Mustafa Özgüroğlu

First Author: Fabrice Barlesi

First Author: Jarushka Naidoo